Imiquimod approved for AKs

Washington - The U.S. Food and Drug Administration (FDA) has granted marketing approval for Aldara (imiquimod) Cream 5 percent for the treatment of actinic keratoses (AK) on the face or scalp in immunocompetent adults. It is the first immune response modifier (IRM) approved for AK.

Related Videos
Related Content

Comorbidities Women With Hair Loss May Experience

March 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Comorbidities Women With Hair Loss May Experience

March 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

Comorbidities Women With Hair Loss May Experience

March 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

The Weekly Roundup: March 20-24

March 24th 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Lebrikizumab Demonstrates Promising Results in Atopic Dermatitis

March 24th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023
© 2023 MJH Life Sciences

All rights reserved.